Patents by Inventor Miklos Feher

Miklos Feher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salt and crystal forms of PLK-4 inhibitor
    Patent number: 11667627
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: June 6, 2023
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR
    Publication number: 20210269428
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Application
    Filed: February 10, 2021
    Publication date: September 2, 2021
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Salt and crystal forms of PLK-4 inhibitor
    Patent number: 10919886
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: February 16, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR
    Publication number: 20200140428
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Application
    Filed: November 6, 2019
    Publication date: May 7, 2020
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Pyrazolopyrimidine compounds
    Patent number: 10570143
    Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 25, 2020
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • Salt and crystal forms of PLK-4 inhibitor
    Patent number: 10472353
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: November 12, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Salt and crystal forms of PLK-4 inhibitor
    Patent number: 10392374
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: August 27, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR
    Publication number: 20190248775
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 15, 2019
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Kinase inhibitors and method of treating cancer
    Patent number: 10358436
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 23, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20190040074
    Abstract: The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 9, 2018
    Publication date: February 7, 2019
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • Pyrazolopyrimidine compounds
    Patent number: 10106545
    Abstract: The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 23, 2018
    Assignee: University Health Network
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • KINASE INHIBITORS AND METHOD OF TREATING CANCER
    Publication number: 20180282306
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Application
    Filed: February 22, 2018
    Publication date: October 4, 2018
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR
    Publication number: 20180155335
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Application
    Filed: February 1, 2018
    Publication date: June 7, 2018
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Kinase inhibitors and method of treating cancer
    Patent number: 9907800
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: March 6, 2018
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • Salt and crystal forms of PLK-4 inhibitor
    Patent number: 9884855
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: February 6, 2018
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20170217966
    Abstract: The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 3, 2017
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • Indazole compounds as kinase inhibitors and method of treating cancer with same
    Patent number: 9580390
    Abstract: The present teaching provide indazole compounds represented by Structural Formulae (I) or (I?) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: February 28, 2017
    Assignee: University Health Network
    Inventors: Heinz W. Pauls, Radoslaw Laufer, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Yunhui Lang, Narendra Kumar B. Patel, Louise G. Edwards, Grace Ng, Peter Brent Sampson, Miklos Feher, Donald E. Awrey
  • Pyrazolopyrimidine compounds
    Patent number: 9573954
    Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: February 21, 2017
    Assignee: University Health Network
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
    Patent number: RE46558
    Abstract: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: September 26, 2017
    Assignee: PALOMA PHARMACEUTICALS, INC.
    Inventors: David I. Sherris, Manjinder Gill, Fupeng Ma, Sanjivanjit Kaur Bhal, Robert Dunn-Dufault, Miklos Feher, Peter Redden, Jonathan Schmidt
  • Kinase inhibitors and method of treating cancer with same
    Patent number: RE47731
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: November 19, 2019
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel